Could a daily coffee habit lower MS risk? New analysis says yes.
People who drink coffee may have a more than 20% lower risk of developing multiple sclerosis (MS) compared with…
Articles by Michela Luciano, PhD
New Tysabri biosimilar Tyruko now on market for relapsing MS
Tyruko (natalizumab-sztn) is now commercially available in the U.S. as the first and only approved biosimilar to Tysabri…
$2.5M gift goes to Case Western team to advance MS research
Scientists at Case Western Reserve University (CWRU) in Ohio will use a new $2.5 million donation from the Thomas F.
Sativex MS spasticity spray now with CNX Therapeutics after sale
Sativex (nabiximols) — a cannabis-based oral spray used to ease spasticity in certain people with multiple sclerosis (MS)…
FDA approves use of robotic exoskeleton for MS rehabilitation
A robotic exoskeleton dubbed Atalante X, which allows people with severe mobility issues to stand upright for rehabilitation exercises, is…
FDA fast tracks DNA therapy for MS-related bladder issue
The U.S. Food and Drug Administration (FDA) granted fast track designation to EG110A, EG 427‘s DNA-based therapy to treat neurogenic…
Kernal gets $48M to develop easier, cheaper CAR T-cell therapies
Kernal Biologics has been awarded up to $48 million in funding to accelerate the development of KR-402, a next-generation…
Diets improve health markers in MS, but don’t affect brain lesions
People with relapsing-remitting multiple sclerosis (RRMS) who started fasting or adopted a ketogenic diet — one low in carbs…
Music therapy for MS may help with motivation, heat sensitivity
A six-week music therapy intervention significantly reduced psychosocial fatigue — or fatigue that interferes with a person’s motivation and ability…
Vibration therapy shows benefits over standard exercise: Trial data
Vibration therapy, which provides mechanical stimulation to activate muscles and sensory receptors, may offer a promising new approach for easing…
Quantum seeks faster UK access for MS therapy Lucid-MS
Quantum Biopharma filed a U.K. innovation passport application to streamline the development and review of Lucid-21-302 (Lucid-MS), a therapy designed…
No MS disability progression for over 60% after stem cell transplant
Nearly two-thirds of people with multiple sclerosis (MS) who underwent a stem cell transplant showed no signs of confirmed…
MS patient enrollment complete in trial testing anti-inflammatory drug
Two of three groups — one composed of people with progressive forms of multiple sclerosis (MS), and the other…
New Tecfidera generic aims to ease financial burden for MS patients
A new low-cost version of Tecfidera, a widely used oral therapy for relapsing forms of multiple sclerosis (MS),…
1st patient imaged in clinical trial of new PET tracer for MS
The first person with multiple sclerosis (MS) has been successfully imaged in a clinical trial evaluating a new positron…
Bionxt prepares for clinical trial testing sublingual cladribine for MS
Bionxt Solutions is getting ready to launch a pilot clinical trial to test BNT23001, its sublingual (under-the-tongue) version of cladribine…
Earlier Ocrevus treatment may reduce cerebellar shrinkage in MS
Early treatment with Ocrevus (ocrelizumab) may help protect the cerebellum, a region of the brain that plays a key…
In MS, culturally tailored exercise programs may benefit Hispanics
Exercise programs that are culturally tailored to Hispanics with multiple sclerosis (MS) may help these patients engage in regular…
Online training offers real-world, cognitive benefits for MS patients
An online training program for managing memory and cognitive difficulties may help people with multiple sclerosis (MS), a study…
Rituximab as effective as Ocrevus as RRMS treatment: Study in Egypt
Rituximab, sometimes used off-label as a multiple sclerosis (MS) treatment, may be as effective — at a much…
Age, education linked to sexual dysfunction in women with MS
Sexual dysfunction affects 80% of women in Iran with multiple sclerosis (MS), with older age and lower education levels…
Fatigue significantly contributes to impaired well-being in MS: Study
Nearly 50% of people with multiple sclerosis (MS) report pronounced fatigue, which has a significantly negative effect on their…
First-line Tysabri better at reducing MS relapse rates, healthcare use
Starting Tysabri (natalizumab) early in multiple sclerosis (MS) treatment may lead to better outcomes, including greater reductions in…
Cognitive impairment found to be common in untreated MS patients
Cognitive impairment is common in people with multiple sclerosis (MS) who have not previously received treatment, affecting about 1…
Myrobalan wins grant for MS remyelination candidate MRO-002
Myrobalan Therapeutics has been awarded a grant of more than $850,000 from the National Multiple Sclerosis Society to advance…
Patients on B-cell therapies less likely to stop treatment: Study
People with multiple sclerosis (MS) who receive anti-CD20 therapies such as Ocrevus (ocrelizumab) are significantly less likely to…